Study Shows Durable Viral Suppression of Boosted REYATAZ in Treatment-experienced HIV Patients

EurekAlert! -- (GLASGOW, 9 November 2010) – Results from a European Observational Study, which included 1,294 antiretroviral (ARV)-experienced patients presented today at the Tenth International Congress on Drug Therapy in HIV Infection (HIV10), demonstrated a low rate of discontinuation and sustained virologic suppression with REYATAZ® (atazanavir)/ritonavir-based regimens over a follow-up period of up to five years.1